196 related articles for article (PubMed ID: 30838908)
1. Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.
Keyloun KR; Lofgren E; Hebert S
J Med Econ; 2019 Jul; 22(7):652-661. PubMed ID: 30838908
[No Abstract] [Full Text] [Related]
2. Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations.
Lodise TP; Fan W; Sulham KA
Clin Ther; 2016 Jan; 38(1):136-48. PubMed ID: 26708118
[TBL] [Abstract][Full Text] [Related]
3. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Huang X; Beresford E; Lodise T; Friedland HD
Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
[TBL] [Abstract][Full Text] [Related]
5. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
6. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.
Jensen IS; Lodise TP; Fan W; Wu C; Cyr PL; Nicolau DP; DuFour S; Sulham KA
Clin Drug Investig; 2016 Feb; 36(2):157-68. PubMed ID: 26692006
[TBL] [Abstract][Full Text] [Related]
7. Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections.
Revankar N; Ward AJ; Pelligra CG; Kongnakorn T; Fan W; LaPensee KT
J Med Econ; 2014 Oct; 17(10):730-40. PubMed ID: 25019580
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States.
Keyloun KR; Weber DJ; Gardstein BM; Berger A; Gillard P; Ganz ML
Hosp Pract (1995); 2018 Dec; 46(5):278-286. PubMed ID: 30067108
[No Abstract] [Full Text] [Related]
9. Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries.
Marcellusi A; Viti R; Sciattella P; Sarmati L; Streinu-Cercel A; Pana A; Espin J; Horcajada JP; Favato G; Andretta D; Soro M; Andreoni M; Mennini FS
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):581-599. PubMed ID: 30714834
[No Abstract] [Full Text] [Related]
10. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
11. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
Jensen IS; Wu E; Fan W; Lodise TP; Nicolau DP; Dufour S; Cyr PL; Sulham KA
J Manag Care Spec Pharm; 2016 Jun; 22(6):752-64. PubMed ID: 27231802
[TBL] [Abstract][Full Text] [Related]
12. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
J Emerg Med; 2024 Mar; ():. PubMed ID: 38825531
[TBL] [Abstract][Full Text] [Related]
13. The Potential Utility of Single-Dose Long-Acting Intravenous Antibiotics for Acute Bacterial Skin and Skin-Structure Infections in the Emergency Department.
Weant KA; Gregory H
Adv Emerg Nurs J; 2023 Jul-Sep 01; 45(3):177-186. PubMed ID: 37501267
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department.
Almarzoky Abuhussain SS; Burak MA; Kohman KN; Jacknin G; Tart SB; Hobbs ALV; Adams DK; Nailor MD; Keyloun KR; Nicolau DP; Kuti JL
BMC Health Serv Res; 2018 Dec; 18(1):932. PubMed ID: 30514295
[TBL] [Abstract][Full Text] [Related]
15. Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis.
Helton B; MacWhinnie A; Minor SB; Lodise TP; Rafferty KD; Allison SL
Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):20-29. PubMed ID: 32588384
[TBL] [Abstract][Full Text] [Related]
16. Identification of Patient Characteristics Influencing Setting of Care Decisions for Patients With Acute Bacterial Skin and Skin Structure Infections: Results of a Discrete Choice Experiment.
Lane S; Johnston K; Sulham KA; Syed I; Pollack CV; Holland T; Nathwani D
Clin Ther; 2016 Mar; 38(3):531-44; quiz 544.e1-9. PubMed ID: 26874786
[TBL] [Abstract][Full Text] [Related]
17. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
Oliva A; Carbonara S; Cianci V; Crapis M; Di Domenico EG; Falcone M; Galardo G; Durante-Mangoni E; Venditti M
Expert Rev Anti Infect Ther; 2023; 21(7):703-721. PubMed ID: 37227028
[TBL] [Abstract][Full Text] [Related]
18. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion.
Bosso JA; Casapao AM; Edwards J; Klinker K; McCoy C; Nicolau DP; Perez KK; Marcarelli A; Dua D
Hosp Pract (1995); 2016 Oct; 44(4):183-189. PubMed ID: 27598313
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin Use in Patients Discharged From the Emergency Department: A Retrospective Observational Cohort Study.
Mueller K; McCammon C; Skrupky L; Fuller BM
J Emerg Med; 2015 Jul; 49(1):50-7. PubMed ID: 25802166
[TBL] [Abstract][Full Text] [Related]
20. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital.
Pollack CV; Amin A; Ford WT; Finley R; Kaye KS; Nguyen HH; Rybak MJ; Talan D
J Emerg Med; 2015 Apr; 48(4):508-19. PubMed ID: 25605319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
